A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria may apply.
medinfo@incyte.com1.855.463.3463
eumedinfo@incyte.com+800 00027423
Washington D.C., District of Columbia 20007, United States
Washington D.C., District of Columbia 20016, United States
Århus N, 08200, Denmark
Kahoku-gun, 920-0293, Japan
Kashiwa-shi, 277-8577, Japan
Mitaka-shi, 181-8611, Japan
Shinjuku-ku, 160-0023, Japan